Zeo ScientifiX Inc (ZEOX)

[soupoftheday]

$BPSR - Forbes - Promising Covid Cures

https://www.forbes.com/sites/genemarcial/2020/05/21/investors-search-for-promising-covid-cures/?fbclid=IwAR2djXaUBR_V6nxoNerdcjuA4E-Jgo6AXj2tcoZyGg5slBluoHQHWE4zeUo#410cad9b3276

One is Organicell Regenerative Medicine, Inc. (BPSR), a Florida-based company. Organicell recently received Food and Drug Administration approval to proceed with an investigational new drug (IND) study to test whether synthetically designed cells could help patients who developed a deadly immune reaction to the coronavirus.

Scheduled to commence immediately, the trial is the first randomized, placebo controlled, Phase 1/Phase 2 multi-center clinical trial investigating the safety and potential efficacy of Organicell Flow for Covid-19.

Importantly, Organicell has a successful track record of working with leading medical research centers on clinical trials. Previously, for instance, Organicell teamed up with the University of Miami to complete pre-clinical studies in therapeutic areas such as pediatric pulmonary disorder.

Earlier this week, Organicell announced the Food and Drug Administration has authorized two emergency compassionate-use investigational new drug applications, each for a single patient severely ill with Covid-19. These patients were first treated with Organicell Flow on May 14 at Landmark Hospital in Athens, GA.

Over the course of 12 years of research and clinical development, Organicell has developed novel and all-natural cell-derived nanoparticles that play a critical role in cell-to-cell communication. Containing rich levels of exosome, Organicell’s biological therapeutics are designed for treating degenerative diseases, and have been shown to promote tissue homeostasis and repair in animal studies. In fact, Organicell has linked the exosome miRNA composition to several disease pathways, highlighting a therapeutic potential for a broad array of conditions that can be safely translated to effective therapies.